Education
About Us
Working with TipRanks
Follow Us
Cerus Corporation (CERS)
:CERS
CERS Stock Chart & Stats
$1.63
-$0.02(-1.22%)
At close: 4:00 PM EST
$1.63
-$0.02(-1.22%)
Day’s Range― - ―
52-Week Range$1.12 - $2.24
Previous CloseN/A
Volume302.69K
Average Volume (3M)1.22M
Market Cap
$338.07M
Enterprise Value$325.42M
Total Cash (Recent Filing)$78.51M
Total Debt (Recent Filing)$98.19M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Feb 19, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding192,087,500
10 Day Avg. Volume1,185,582
30 Day Avg. Volume1,221,935
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)5.06
Price to Sales (P/S)1.58
P/FCF Ratio33.35
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.63
Enterprise Value/Gross Profit2.96
Enterprise Value/Ebitda-55.42
Forecast
1Y Price Target
$4.50Price Target Upside176.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$231.03M
Bulls Say, Bears Say
Bulls Say
Market ValueShares of CERS trade below small cap peers, indicating potential value compared to others in the market.
Revenue GrowthCerus delivered a Q3 beat and raise, driven by ongoing growth in INTERCEPT platelets as well as its newer IFC product which grew by 70% Y/Y.
Revenue GuidanceCERS raised its 2025 revenue guide, showing confidence in future financial performance.
Bears Say
Regulatory DelaysTimelines for the EU review for a CE marking for INTERCEPT Red Blood Cells (RBCs) have been pushed out by at least six months, which is viewed as a very important catalyst for the stock.
Stock PerformanceCERS shares have lagged in recent months and the stock is near its 52-week low.
Cerus News
CERS FAQ
What was Cerus Corporation’s price range in the past 12 months?
Cerus Corporation lowest stock price was $1.12 and its highest was $2.23 in the past 12 months.
What is Cerus Corporation’s market cap?
Cerus Corporation’s market cap is $338.07M.
When is Cerus Corporation’s upcoming earnings report date?
Cerus Corporation’s upcoming earnings report date is Feb 19, 2026 which is in 78 days.
How were Cerus Corporation’s earnings last quarter?
Cerus Corporation released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.028 by $0.028.
Is Cerus Corporation overvalued?
According to Wall Street analysts Cerus Corporation’s price is currently Undervalued.
Does Cerus Corporation pay dividends?
Cerus Corporation does not currently pay dividends.
What is Cerus Corporation’s EPS estimate?
Cerus Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Cerus Corporation have?
Cerus Corporation has 192,087,500 shares outstanding.
What happened to Cerus Corporation’s price movement after its last earnings report?
Cerus Corporation reported an EPS of $0 in its last earnings report, beating expectations of -$0.028. Following the earnings report the stock price went up 21.277%.
Which hedge fund is a major shareholder of Cerus Corporation?
Currently, no hedge funds are holding shares in CERS
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (176.07% Upside)
$4.50 (176.07% Upside)
Blogger Sentiment
Bullish
CERS Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 8.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $31.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.29%
12-Months-Change
Fundamentals
Return on Equity
-27.77%
Trailing 12-Months
Asset Growth
13.53%
Trailing 12-Months
Company Description
Cerus Corporation
Cerus Corporation (CERS) is a biomedical company focused on blood safety and the development of innovative therapies for transfusion medicine. The company operates primarily in the healthcare sector, specializing in pathogen reduction technologies for blood components. Its core product is the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections in plasma, platelets, and red blood cells. Cerus aims to enhance the safety and availability of blood products through its advanced technology.
CERS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Cerus Corporation's earnings call for Q3 2025 highlighted significant revenue growth and positive financial performance, driven by strong demand for INTERCEPT products and successful international expansion efforts. However, the company faces challenges with gross margin pressures and regulatory delays in Europe. Despite these hurdles, the overall outlook remains optimistic with raised revenue guidance and continued focus on operational execution.View all CERS earnings summariesCERS Stock 12 Month Forecast
Average Price Target
$4.50
▲(176.07% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―
Ownership Overview
4.90% Insiders
14.03% Mutual Funds
32.96% Other Institutional Investors
28.95% Public Companies and
Individual Investors